Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC). The median overall survival (OS) was notably better in the atezolizumab/bevacizumab group. However, for HCC patients with intrahepatic macrovascular invasion (MVI), the prognosis remains poor, indicating a significant unmet need in this group. External Beam Radiotherapy (EBRT) has shown promising results in treating HCC with MVI, especially when used in combination with trans-arterial chemoembolization (TACE).

Trial Details

NCT ID
NCT05992220
Phase
PHASE2
Sponsor
Asan Medical Center
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
  • Atezolizumab plus bevacizumab
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Older than 19 years of age, lower than 80 years of age
  • Child-Pugh class A hepatic function
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
  • Patients with HCC \[diagnosed according to AASLD guidelines\] invading the intrahepatic vascular system

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →